N.J. invests $1.5M into HIE network

New Jersey is investing $1.57 million into the development of a new health information network.

The New Jersey Health Information Network (NJHIN) will connect regional health information organizations that are currently exchanging data among local healthcare providers.

NJHIN, which will initially connect about 2,000 providers, is expected to become operational this year. Healthcare providers will connect to the network through their regional health information organization, which is a group of physician offices, hospitals and healthcare stakeholders such as laboratories that come together to electronically exchange patient health information.

New Jersey Health Commissioner Mary E. O'Dowd announced the NJHIN project at the New Jersey Technology Council's Health Information Technology Summit in Princeton.

The NJHIN coalition that received this grant award includes the following members:

  • Jersey Health Connect, the coalition lead and a health information organization that connects northern and central New Jersey healthcare providers;
  • Health-e-cITi-NJ, a health information organization that connects greater Newark area providers;
  • Camden HIE, a health information organization that connects Camden area providers;
  • NJSHINE, a health information organization that connects southern New Jersey healthcare providers;
  • Virtua, an integrated delivery network based in southern New Jersey; and
  • NJ-HITEC, New Jersey's regional extension center dedicated to helping office-based physicians adopt and demonstrate meaningful use of certified electronic health record technology

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.